Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKS 5461 in MDD with Inadequate Response
NCT01500200Phase 2Completed
- Sponsor
- Alkermes
- Start
- Dec 2011
- Primary completion
- Mar 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of buprenorphine + samidorphan in major depressive disorder (MDD), sponsored by Alkermes. Started Dec 2011; status: completed.
02
Drugs
buprenorphine + samidorphan
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01500200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01500200.